Earlier Today, GSK Announced Headline Results Of A Phase 2 Trial For Its MRNA Seasonal Influenza Vaccine Program, Demonstrating A And B Strain Immune Responses Relative To Standard Of Care In Both Younger And Older Adults
Earlier Today, GSK Announced Headline Results Of A Phase 2 Trial For Its MRNA Seasonal Influenza Vaccine Program, Demonstrating A And B Strain Immune Responses Relative To Standard Of Care In Both Younger And Older Adults
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated